Patient Derived Xenograft (PDX) Models Market Report 2026

Patient Derived Xenograft (PDX) Models Market Overview

• Patient Derived Xenograft (PDX) Models market size has reached to $0.47 billion in 2025 • Expected to grow to $0.92 billion in 2030 at a compound annual growth rate (CAGR) of 14% • Growth Driver: Personalized Medicine's Impact On The PDX Models Market • Market Trend: Advancements in Patient-Derived Xenograft (PDX) Models and Bioluminescence Imaging for Glioblastoma Research • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Patient Derived Xenograft (PDX) Models Market?

Patient-derived xenograft (PDX) models involve transplanting human tumor tissue into immunodeficient animal hosts. They mimic the complexity of human tumors more closely than traditional cell line models. PDX models are crucial for studying tumor biology and testing potential cancer therapies before clinical trials. The main types in the patient derived xenograft (PDX) models market are mice models and rat models. Mice models refer to laboratory mice genetically modified or bred to study specific biological processes, diseases, or responses to treatments, aiding in biomedical and pharmaceutical research. The various techniques including heterotopic implantation and orthotropic implantation, and several types of tumors including gastrointestinal tumor models, lung tumor models, hematological tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, and others. PDX models find application in preclinical drug development, precision medicine, co-clinical trials, and basic cancer research across academic institutions, research organizations, pharmaceuticals, biotechnology firms, and others.

What Is The Patient Derived Xenograft (PDX) Models Market Growth Forecast?

The patient derived xenograft (pdx) models market size is expected to see rapid growth in the next few years. It will grow to $0.92 billion in 2030 at a compound annual growth rate (CAGR) of 14.0%. The growth in the forecast period can be attributed to rising adoption of pdx models for precision medicine, increasing investment in humanized mouse and rat models, growth of co-clinical trial programs, expansion of contract research services offering pdx solutions, increasing use of pdx models for immunotherapy and targeted therapy evaluation. Major trends in the forecast period include increasing adoption of pdx models for preclinical drug development, rising focus on personalized cancer research using pdx models, growing integration of digital platforms for tumor data management, increasing utilization of humanized and genetically modified models, rising expansion of co-clinical trials leveraging pdx models.

What Is The Driver Of The Patient Derived Xenograft (PDX) Models Market?

The demand for personalized medicine is expected to propel the growth of the patient-derived xenograft (PDX) models market going forward. Personalized medicine involves tailoring medical treatment to each patient's specific characteristics, considering factors such as genetics, environment, and lifestyle. The demand for personalized medicine is increasing due to advancements in genomic research, which enable tailored treatments based on individual genetic profiles, leading to more effective and targeted healthcare outcomes. Patient-derived xenograft (PDX) models aid personalized medicine by allowing the testing of individual patient tumors to predict treatment responses and tailor therapies accordingly. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit umbrella organization, in 2023, the FDA approved 16 new personalized treatments for rare diseases, a significant increase from six approvals in 2022. Therefore, the demand for personalized medicine drives the patient-derived xenograft (PDX) models market growth.

Key Players In The Global Patient Derived Xenograft (PDX) Models Market

Major companies operating in the patient derived xenograft (pdx) models market are WuXi AppTec Co Ltd, Charles River Laboratories International Inc, The Jackson Laboratory, Inotiv Inc, Taconic Biosciences Inc, Crown Bioscience Inc, Champions Oncology Inc, Certis Oncology Solutions Inc, EPO Experimental Pharmacology & Oncology Berlin‑Buch GmbH, InnoSer, Envigo, Oncodesign Services SA, Horizon Discovery Ltd, Pharmatest Services Ltd, Hera BioLabs, Xenopat, Noble Life Sciences, Medicilon, TheraIndx Life Sciences, Invivocue, InVitro Research Solutions Private Limited, NexusPharma, Mediford Corporation, GemPharmatech Co Ltd.

Global Patient Derived Xenograft (PDX) Models Market Trends and Insights

Major companies operating in the patient-derived xenograft (PDX) models market are developing innovative models with in vivo bioluminescence imaging capabilities to enable real-time monitoring of tumor growth. In vivo bioluminescence imaging helps PDX models by enabling noninvasive real-time monitoring of tumor metastasis and treatment responses, enhancing the effectiveness of preclinical research in drug development. For instance, in March 2024, InVitro Research Solutions Private Limited, an India-based Contract Research Organization (CRO), launched an innovative orthotopic model of human glioblastoma in NSG-SGM3 mice by using patient-derived xenografts (PDX) and in vivo bioluminescence imaging. This model aims to enable personalized treatment of glioblastoma, the most common and aggressive type of brain cancer. These models are critical for understanding glioblastoma biology and evaluating new targeted therapies and immunotherapies to improve outcomes.

What Are Latest Mergers And Acquisitions In The Patient Derived Xenograft (PDX) Models Market?

In October 2024, Merck & Co., Inc., a US-based pharmaceutical company, acquired Modifi Biosciences, Inc., for $1.3 billion. This acquisition aligns with Merck's strategy to strengthen its oncology portfolio by integrating Modifi's innovative research, including preclinical drug candidates and patient-derived xenograft model data, to advance therapies for cancers with DNA repair deficiencies. Modifi Biosciences, Inc., a US-based biotechnology firm specializing in cancer therapeutics through direct DNA modification.

What Defines the Patient Derived Xenograft (PDX) Models Market?

The patient derived xenograft (PDX) models market includes revenues earned by entities by providing services such as evaluating drug efficacy, studying tumor biology, and predicting patient-specific treatment responses in preclinical cancer research. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Patient Derived Xenograft (PDX) Models Market Report 2026?

The patient derived xenograft (pdx) models market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the patient derived xenograft (pdx) models industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.